Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.420
+0.030 (2.16%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Company Description
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.
The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation
| Country | United States |
| Founded | 1990 |
| IPO Date | Jun 30, 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 229 |
| CEO | Dawn Bir |
Contact Details
Address: 919 East Hillsdale Boulevard, Suite 250 Foster City, California 94404 United States | |
| Phone | 650 473 7700 |
| Website | geron.com |
Stock Details
| Ticker Symbol | GERN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000886744 |
| CUSIP Number | 374163103 |
| ISIN Number | US3741631036 |
| Employer ID | 75-2287752 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dawn Carter Bir | Interim President and Chief Executive Officer and Director |
| Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial and Accounting Officer |
| Dr. Andrew J. Grethlein Ph.D. | Executive Vice President and Chief Operating Officer |
| James Ziegler M.B.A. | Executive Vice President and Chief Commercial Officer |
| Dr. Joseph Emile Eid M.D. | Executive Vice President of Research and Development |
| Aron Feingold | Vice President of Investor Relations and Corporate Communications |
| Scott Samuels | Executive Vice President, Chief Legal Officer and Secretary |
| Shannon T. Odam | Executive Vice President and Chief People Officer |
| Dr. Faye Feller M.D. | Executive Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2025 | ARS | Filing |
| Apr 8, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2025 | SCHEDULE 13G | Filing |
| Mar 17, 2025 | 8-K/A | [Amend] Current report |
| Mar 11, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | 8-K | Current Report |